Method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan

A technology of dimethylbenzanthracene and fucoidan, applied in medical preparations containing active ingredients, pharmaceutical formulas, organic active ingredients, etc. The problem of low anti-tumor effect of sugar gum can achieve the effect of enhancing anti-tumor immunity and alleviating immunosuppression

Inactive Publication Date: 2017-05-31
QINGDAO UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few in vivo experiments on the anti-tumor effect of fucoidan, and they are limited to xenograft tumor animal models, which cannot completely simulate the occurrence and development of tumors in vivo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan
  • Method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan
  • Method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The present invention will be further described below in combination with specific embodiments.

[0016] In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described here are only used to explain the present invention, and are not intended to limit the present invention.

[0017] This specific embodiment adopts the following technical scheme: it includes experimental animals, medicines and reagents; the experimental animals are 60 clean grade female SD rats, 2 months old, with a body weight of 200g, and the rats are raised in a standard animal laboratory. Cage feeding, 7 to 8 birds per cage, free access to water and food, natural light, adaptive feeding for one week after purchase; Tween 80, IL-4, IL-6, IL-10, IL-12, IFN-γ, TNF-α, anti-TCRαβ-FITC antibody, anti-CD161...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan, which relates to the technical field of mammary cancer inhibition. Sixty SPF (Specific Pathogen Free ) grade female SD (Sprague-Dawley) rats are randomly divided into a blank control group, a model control group, a low-dose fucoidan intervention group and a high-dose fucoidan intervention group according to body weights, fifteen rats in each group, the rats are killed after sixteen weeks, the incubation period and tumor inhibition rate of the mammary cancer of each group of rats are calculated, and thymus indexes, spleen indexes and the like are calculated. ELISA (enzyme-linked immunosorbent assay) is adopted to assay the levels of interleukins IL-6, IL-10 and IL-12, interferon-Gamma and transforming growth factor-Beta in serum, and a flow cytometer is utilized to assay the activity of NK (natural killer) cells in the peripheral blood of the rats and the cell percentage of the T-lymphocytes subset. The method has the following advantages that the method can regulate the immunity of rats, enhance antitumor immunity and relieve the immunosuppression of tumors, and the regulation of the activity of immune cells by fucoidan is one of the mechanisms of fucoidan in inhibiting the occurrence of mammary cancer.

Description

technical field [0001] The invention relates to the technical field of breast cancer inhibition, in particular to a method for inhibiting breast cancer in rats induced by dimethylbenzanthracene by fucoidan. Background technique [0002] Breast cancer is one of the most common malignant tumors that endanger women's health. The survey found that the incidence of breast cancer has gradually increased in the past 50 years, accounting for about 31% of women's tumors. Although the comprehensive treatment methods (surgery, chemotherapy, radiotherapy, and endocrine therapy) widely used now have greatly reduced the mortality rate of breast cancer, more than one-third of breast cancer patients still have postoperative recurrence and easy to die. The characteristics of metastases are not sensitive to endocrine therapy, the treatment effect and prognosis are poor, and the side effects of chemotherapy are obvious, so far there is still a lack of satisfactory comprehensive treatment plan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/737A61P35/00
CPCA61K31/737
Inventor 薛美兰梁惠葛银林薛传星王晓杰
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap